CITIUS PHARMACEUTICALS INC (CTXR)

US17322U2078 - Common Stock

2.6  +0.03 (+1.17%)

After market: 2.57 -0.03 (-1.15%)

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (12/20/2024, 8:04:23 PM)

After market: 2.57 -0.03 (-1.15%)

2.6

+0.03 (+1.17%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-2400%
Sales Q2Q%N/A
CRS0.62
6 Month-82.92%
Overview
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)12-27 2024-12-27/amc
Ins Owners6.82%
Inst Owners17%
Market Cap18.80M
Shares7.23M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
Short Float %N/A
Short Ratio0.12
IPO08-03 2017-08-03
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CTXR Daily chart

Company Profile

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 22 full-time employees. The company went IPO on 2017-08-03. The company develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Company Info

CITIUS PHARMACEUTICALS INC

11 Commerce Dr Fl 1

Cranford NEW JERSEY 07016

P: 19089676677

CEO: Myron Holubiak

Employees: 22

Website: https://www.citiuspharma.com/

CTXR News

News Imagea month ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

/PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...

News Imagea month ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split...

News Imagea month ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

/PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...

News Imagea month ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

/PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...

News Imagea month ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR),...

News Image4 months ago - Citius Pharmaceuticals, Inc.Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will...

CTXR Twits

Here you can normally see the latest stock twits on CTXR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example